A Prime/Boost PfCS14KM/MVA-sPfCSM Vaccination Protocol Generates Robust CD8\(^{+}\) T Cell and Antibody Responses to *Plasmodium falciparum* Circumsporozoite Protein and Protects Mice against Malaria

Aneesh Vijayan,\(^{a}\) Ernesto Mejías-Pérez,\(^{a}\) Diego A. Espinosa,\(^{a}\) Suresh C. Raman,\(^{a}\) Carlos Oscar S. Sorzano,\(^{c}\) Fidel Zavala,\(^{b}\) Mariano Esteban\(^{a}\)

Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB-CSIC), Madrid, Spain; Department of Molecular Microbiology and Immunology, Malaria Research Institute, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA; Biocomputing Unit, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB-CSIC), Madrid, Spain

**ABSTRACT** Vaccines against the preerythrocytic stages of malaria are appealing because the parasite can be eliminated before disease onset and because they offer the unique possibility of targeting the parasite with both antibodies and T cells. Although the role of CD8\(^{+}\) T cells in preerythrocytic malaria stages is well documented, a highly effective T cell-inducing vaccine remains to be advanced. Here we report the development of a prime-boost immunization regimen with the *Plasmodium falciparum* circumsporozoite protein (PfCS) fused to the oligomer-forming vaccinia virus A27 protein and a modified vaccinia virus Ankara (MVA) vector expressing PfCS. This protocol induced polyfunctional CD8\(^{+}\) T cells with an effector memory phenotype and high PfCS antibody levels. These immune responses correlated with inhibition of liver-stage parasitemia in 80% and sterile protection in 40% of mice challenged with a transgenic *P. berghei* parasite line that expressed PfCS. Our findings underscore the potential of T and B cell immunization strategies for improving protective effectiveness against malaria.

**KEYWORDS** *P. falciparum* circumsporozoite, oligomeric PfCS, MVA-PfCS, polyfunctional CD8\(^{+}\) T cells, antibodies, transgenic *P. berghei*, malaria vaccine

Malaria continues to be a global killer, with annual mortalities of as high as 438,000 for all age groups and 306,000 for children under the age of 5 years (http://www.who.int/malaria/media/world-malaria-report-2015/en/). The circumsporozoite (CS) protein, the major surface component of the malaria sporozoite, has been studied extensively and is a leading preerythrocytic vaccine candidate (1–3). Many studies highlight the importance of CS protein-specific antibodies and T cells in mediating protection in both animals and human subjects (3–8). Although RTS,S, currently the only malaria vaccine being considered for licensing, is based on the CS protein, its protective efficacy is only 50% in children for the first year and tends to decline rapidly (9–11). RTS,S-mediated protection is attributed mainly to the high titer of anti-CS protein antibodies (9–12). An ideal preerythrocytic vaccine should also generate polyfunctional cytotoxic T cell responses that target liver stages of the parasite. The next generation of preerythrocytic malaria vaccines should thus aim at inducing both humoral and cell-mediated immunity. Studies with murine malaria models have shown that to achieve protection, large numbers of CS protein-specific memory CD8\(^{+}\) T cells are needed (13).
It is therefore imperative for protection that a successful preerythrocytic malaria vaccine must generate polyfunctional memory CD8\(^+\) T cells as well as high antibody levels.

Previous studies showed that multimerization of an antigen enhances its immunogenicity (14, 15). In agreement with these studies, we showed that oligomerization of the CS protein from *Plasmodium yoelii* by fusion with the vaccinia virus 14K protein (A27) enhances its immunogenicity by inducing a type I interferon response in macrophages (8). A recent study reported that a similar type I interferon response, mediated via IRF-3 and STAT-1, is essential for clearing liver-stage parasitemia (16). These studies highlight the importance of the innate immune system in controlling the liver stage of malaria and indicate that formulations able to generate similar responses may aid in the development of next-generation malaria vaccines.

In this study, we describe an immunization regimen that generates *P. falciparum* CS protein (PfCS)-specific polyfunctional memory CD8\(^+\) T cells and high antibody titers able to inhibit infection by a transgenic rodent *P. berghei* parasite expressing PfCS. The strategy is based on priming with oligomeric PfCS fused to the vaccinia virus 14K protein and boosting with a recombinant modified vaccinia virus Ankara (MVA) strain expressing PfCS. Our findings underscore the importance of an immunization protocol that controls the preerythrocytic liver stage of the parasite and may warrant development as a next-generation candidate for a malaria vaccine.

RESULTS

Expression of the oligomeric CS protein from *P. falciparum*. A truncated version of the PfCS gene from the *Plasmodium* 3D7 isolate (NCBI reference sequence XM_001351086), excluding the native signal peptide and the C-terminal glycosylphosphatidylinositol (GPI) motif, was amplified from the plasmid pIC-CSPfFL. A point mutation was introduced by site-directed mutagenesis to generate a CD8\(^+\) T cell epitope that is absent in the *P. falciparum* 3D7 strain but is found in other *P. falciparum* isolates, such as 7G8 and T4. In the region containing the sequence \(308\text{DYANDIEKKI}317\), the A residue at position 310 was thus replaced by E to give \(308\text{DYENDIEKKI}317\) (Fig. 1A), which is the only H-2\(^K\)-restricted *P. falciparum* CD8\(^+\) T cell epitope recognized in mice and also partially overlaps the human epitope recognized by HLA-B35 (17). The amplified fragment was fused to a vaccinia virus A27L gene lacking the codons for the first 20 amino acids and then cloned into the pGEX-6P bacterial expression vector as described previously (8). Protein purity was analyzed by SDS-PAGE followed by Coomassie blue staining (Fig. 1B). Immunoblots using monoclonal antibody (MAb) 2A10, a neutralizing antibody against the PfCS repeat region, showed that under nonreducing conditions, the protein existed mainly as high-molecular-mass oligomers (Fig. 1C); under reducing conditions, the protein was present as \(55\)-kDa monomers. The recognition profile for a polyclonal antibody to the vaccinia virus 14K protein was similar to that for MAb 2A10 (not shown). These results corroborated our previous study showing that 14K fusion with the CS protein in a disulfide-dependent manner (18, 19) aids in the formation of high-molecular-mass oligomers (8).

Generation and characterization of recombinant vaccinia virus MVA-sPfCS\(^M\). The construction and characterization of an MVA construct expressing the full-length *P. falciparum* CS protein were described previously (20). Here we generated a recombinant virus encoding a mutated (A\(_{310}\) to E\(_{310}\)) CS protein lacking the GPI motif, in which the native signal sequence was replaced by a synthetic signal peptide from human immunodeficiency virus type 1 (HIV-1) glycoprotein 120 (gp120) to enable secretion of the protein (Fig. 2A). We used PCR and DNA sequencing of purified viral stocks to evaluate the integrity and stability of the recombinant virus (Fig. 2B). Immunoblots using monoclonal antibody (MAb) 2A10, a neutralizing antibody against the PfCS repeat region, showed that under nonreducing conditions, the protein existed mainly as high-molecular-mass oligomers (Fig. 1C); under reducing conditions, the protein was present as \(~55\)-kDa monomers. The recognition profile for a polyclonal antibody to the vaccinia virus 14K protein was similar to that for MAb 2A10 (not shown). These results corroborated our previous study showing that 14K fusion with the CS protein in a disulfide-dependent manner (18, 19) aids in the formation of high-molecular-mass oligomers (8).

To determine whether expression of the heterologous proteins affected viral replication under permissive conditions, we compared the growth kinetics of wild-type virus to those of the recombinant viruses MVA-PfCS and MVA-sPfCS\(^M\). Expression of the
heterologous antigen did not influence viral replication in permissive chick DF-1 cells (not shown). We thus successfully generated a recombinant MVA strain that is able to express and secrete mutated PfCS from infected cells.

**Generation and characterization of transgenic** *P. berghei*-**P. falciparum** **chimeric parasites.** We generated a *P. berghei* transgenic parasite expressing the full-length *P. falciparum* CS protein (3D7). In this transgenic line, a single amino acid in the CS protein region containing the sequence DYANDIEKKI was modified to incorporate the cytotoxic CD8⁺ T cell epitope DYENDIEKKI. This epitope is not found in the 3D7 strain but is present in other *P. falciparum* isolates (such as 7G8 and T4). Full-length PfCS with the

**FIG 1** Characterization of PfCS14KM recombinant protein. (A) Sequence of the *Plasmodium falciparum* (strain 3D7) CS protein used in this study, lacking the signal sequence and the GPI motif at the C terminus. A mutant form of the CS protein (PfCSM) was generated by introducing an A310 → E310 mutation to generate the CD8⁺ T cell epitope DYENDIEKKI. The purity of the recombinant PfCS14K protein from *Escherichia coli* was evaluated under reducing and nonreducing conditions by Coomassie blue staining (B) and by immunoblotting (W.B) using MAb 2A10 (anti-PfCS) (C).
*P. berghei* native signal sequence was cloned into the CS locus of green fluorescent protein (GFP)-luciferase-expressing *P. berghei* ANKA (Fig. 3A). Transfected parasites were selected by pyrimethamine treatment of infected Swiss Webster mice. The transgenic parasites were cloned by limiting dilution of total parasites obtained from the mice. PCR analysis confirmed recombination at the 5' and 3' ends of the replaced gene (Fig. 3B) and was followed by sequencing of the insert from the cloned isolate (Fig. 3C).

To verify the infectiousness of the cloned isolate of the *P. berghei*-*P. falciparum* transgenic parasite, we compared the chimeric parasite with the wild-type strain. *Aedes stephensi* mosquitoes were allowed to feed on parasite-infected mice. Oocyst counts in mosquito midguts were analyzed after 12 days and were 11011 to 60 for both groups. The development pattern of the transgenic parasite was similar to that of the wild-type parasite (Table 1).

**An immunization regimen based on recombinant protein priming and virus boosting enhances PfCS-specific CD8+ T cell numbers.** The rationale for developing mutated versions of a PfCS-based recombinant protein (PfCS14KM) and a recombinant virus (MVA-sPfCSM) was that our initial studies with unmutated PfCS14K and MVA-PfCS immunization strategies did not elicit T cell responses in BALB/c mice (not shown). Because previous studies described the generation of H-2K-restricted CD8+ T cells specific for the *P. falciparum* CS protein epitope DYENDIEKKI in C3H mice (20), we developed an immunization strategy with PfCS and MVA vectors in which the *P.
A.  

falciparum 3D7 CS protein was modified to incorporate the cytotoxic epitope (Fig. 1A), which we used to define the profile of immune responses in mice (Fig. 4A).

Stimulation of splenocytes from mice immunized with the peptide showed a robust expansion of PfCS-specific CD8^+ T cells during the adaptive and memory phases (Fig. 4B); CD4-specific responses were low for all mouse groups given that the peptide used for stimulation is CD8 specific (Fig. 4C). Mice primed with the oligomeric protein and boosted with the recombinant virus had the highest CD8^+ T cell levels. To determine

**FIG 3** Development of *P. berghei* transgenic parasites expressing a mutant form of PfCS. (A) Scheme of the strategy to replace the CSP gene of GFP-luciferase-expressing *P. berghei* (ANKA) with *P. falciparum* (3D7) CSP incorporating the *P. berghei* signal sequence. A star indicates the location of the nucleotide change introduced to generate the DYENDIEKKI CD8^+ T cell epitope. The annealing sites of the PCR primers used to verify recombination at the CSP locus are indicated at the bottom. Restriction sites are indicated as follows: B, BbsI; K, KpnI; Ka, KasI; P, PacI; and X, XhoI. (B) Using genomic DNA from *P. berghei*-*P. falciparum* (*P.b.-P.f.*) CSP-FL CD8CT parasites, 5′ and 3′ integration at the CSP locus was verified by PCR. Primers PbcSS′-F and hDHFR′UTR-R yielded a 1,000-bp product, and primers PfcSS′-F and PbCS3′UTR-R yielded a 2,100-bp product. (C) Amino acid sequence of the CS protein in the *P. berghei*-*P. falciparum* CSP-FL CD8CT parasite. The *P. berghei* signal sequence is shown in green, and *P. falciparum* residues are shown in blue. The Ala (A)-to-Glu (E) change introduced to generate the cytotoxic epitope is underlined.
whether PfCS-specific CD4⁺ or CD8⁺ T cells targeted other protein epitopes, we stimulated splenocytes from vaccinated mice with sonicated unmutated recombinant PfCS. Using this approach, we did not detect other H-2K-restricted PfCS-specific CD4⁺ or CD8⁺ T cells, which supported our hypothesis that the cellular response generated by the vaccine regimen was restricted to the CD8⁺ T cell epitope (not shown). Mice primed with protein and boosted with recombinant virus maintained similar levels of CS peptide-specific CD8⁺ T cells at 2 weeks and 2 months postboost (Fig. 4B).

These immunizations generated high titers of PfCS-specific antibodies in the memory phase. The PfCS14KM/PfCS14KM-immunized mouse group produced high levels of PfCS antibodies similar to those for the heterologous PfCS14KM/MVA-sPfCSM prime-boost group (Fig. 4D). Since the vaccination protocols led to antibody production, the low CD4⁺ T cell responses after splenocyte stimulation with whole PfCS might be linked to the use of C3H mice, which are low responders to immunization using synthetic peptides with PfCS CD4⁺ T cell epitopes (21).

These data suggest that PfCS14KM priming/MVA-sPfCSM boosting increased H-2K-restricted CS protein-specific splenic CD8⁺ T cells during the adaptive and memory phases, in contrast to the results of homologous immunogen combination. This strategy also produced high anti-PfCS titers comparable to those induced by homologous protein PfCS14KM priming and boosting.

**PfCS14KM/MVA-sPfCSM immunization triggers polyfunctional PfCS-specific CD8⁺ T cell responses.** Having established that the PfCS14KM/MVA-sPfCSM prime/boost immunization protocol generated PfCS-specific CD8⁺ T cells, we characterized these T cells based on their polyfunctional responses. Polymodularity was defined by the ability of the antigen-specific T cells to simultaneously produce two or more cytokines (gamma interferon [IFN-γ], tumor necrosis factor alpha [TNF-α], and/or interleukin-2 [IL-2]) and/or perforin (CD107a) after peptide stimulation of splenocytes from vaccinated mice. A strongly polyfunctional T cell secretes a large number of cytokines (quadruple-positive population). Intracellular cytokine staining (ICS) analysis of adaptive and memory immune responses clearly showed a shift in CD8⁺ T cell polyfunctionality in PfCS14KM-primed/MVA-sPfCSM-boosted mice (Fig. 5). Although the size of the CS protein-specific H-2K-restricted CD8⁺ T cell population remained unchanged between the adaptive and memory phases, there was a significant shift in polyfunctionality. Most responses during the adaptive phase in protein-primed/recombinant virus-boosted mice were monofunctional (CD107a⁺ or IFN-γ⁺), bifunctional (CD107a⁺ IFN-γ⁺), or trifunctional (CD107a⁺ IFN-γ⁺ TNF-α⁺) (Fig. 5A). We found a 6-fold increase in CD107a⁺ IFN-γ⁺ TNF-α⁺ IL-2⁺ CD8⁺ T cells (P < 0.005) in this group during the memory compared to the adaptive phase (Fig. 5). The proportion of CD107a⁺ IFN-γ⁺ TNF-α⁺ IL-2⁺ CD8⁺ T cells (quadruple positive) increased 31% during the memory phase (P < 0.005), while the triple-positive population doubled, to 40% of total CD8⁺ T cells (P < 0.05), compared to the levels of the same populations in the adaptive phase (Fig. 5A and B, pie charts).

**PfCS14KM/MVA-sPfCSM immunization enhances effector memory T cell levels.** The correlation between induction of memory CD8⁺ T cells specific to liver-stage...
FIG 4 Levels of PfCS (peptide)-specific CD8⁺ and CD4⁺ T cells and antibodies generated by different immunization protocols. (A) Immunization schedule. C3H (H-2b) mice received distinct combinations of immunogens in a prime/boost approach. For each dose, each mouse received 20 μg protein by the intradermal (i.d.) route or 2 × 10⁷ PFU of MVA-sPfCSM (Continued on next page)
The levels of PfCS-specific IgG antibodies. (Left) Data are presented as OD450 values versus serum dilutions; the maximum T cell subsets (23, 24). Our data showed that the majority of CD8+ T cells generated in response to vaccine had an effector memory phenotype (Fig. 6). Furthermore, we found a 3.5-fold increase in TEff CD8+ T cell levels in the protein/MVA protocol group compared to those in the other groups (P < 0.005). This confirmed that the PfCS14KM/MVA-sPfCSM immunization regimen significantly enhanced development of PfCS-specific CD8+ T cells with an effector memory phenotype.

**Parasite protection in mice immunized with PfCS14KM/MVA-sPfCSM.** Since the protein prime/recombinant virus boost regimen induced larger numbers of polyfunctional CD8+ T cells in mice than those induced by homologous combinations of immunogens, we tested whether the former protocol protected mice after challenge with transgenic *P. berghei* sporozoites expressing the mutated *P. falciparum* CS protein (*P. berghei*-P. falciparum CSP-FL CD8CT). Mice primed with PfCS14KM and boosted with MVA-sPfCSM showed an 80% inhibition of parasite load in the liver compared to the loads of the other groups (Fig. 7A, left half).

To further determine if liver-stage inhibition would be observed after immunization with the unmutated PfCS antigen, which did not generate T cell responses, we tested a prime-boost regimen by using unmutated versions of the recombinant protein (PfCS14K) and virus (MVA-PfCS) (without the A310→E310 substitution). In immunized mice challenged with transgenic *P. berghei* sporozoites expressing the unmutated full-length *P. falciparum* 3D7 CS protein (*P. berghei*-P. falciparum CSP-FL), liver parasite burdens were comparable to those in controls (Fig. 7A, right half). It would be anticipated that mice immunized with PfCS14KM/MVA-sPfCSM and challenged with transgenic *P. berghei* parasites expressing PICSP lacking the H-2K-restricted CD8+ T cell epitope would not be protected and thus would have higher parasite loads, which would further support a protective role for CD8+ T cells. Nonetheless, given the large number of controls needed to allow accurate measurement and interpretation of the relative protective efficacies of the individual immune mechanisms involved, this experiment was not performed.

Finally, we tested whether the reduction in liver-stage parasite burden translates into sterile protection. We observed that 40% of PfCS14KM/MVA-sPfCSM-immunized mice did not develop blood-stage parasitemia after challenge by infectious mosquito bites harboring transgenic *P. berghei* sporozoites expressing the mutated *P. falciparum* CS protein (*P. berghei*-P. falciparum CSP-FL CD8CT) (Fig. 7B). The PfCS14KM prime/MVA-sPfCSM boost regimen is thus an effective vaccine protocol for controlling parasite loads in the liver and achieving sterile protection.

**DISCUSSION**

The aims of this study were to demonstrate the potency of a novel malaria vaccine candidate generated by fusion of the *P. falciparum* CS protein with the vaccinia virus antigens and malaria protection is well established for small mammals as well as humans (6, 7, 22). To characterize the phenotype of CS protein-specific memory CD8+ T cells generated in response to vaccination, we used the CD127 and CD62L surface markers. These markers differentiate memory cells into central memory (TEm, CD127lo CD62Lhi), effector memory (TEm, CD127hi CD62Llo), and effector (Te: CD127lo CD62Llo) T cell subsets (23, 24).

**FIG 4 Legend (Continued)**

by the intraperitoneal (i.p.) route. The groups received the following immunogens: group 1, protein PfCS14KM/protein PfCS14K (i.d.); group 2, recombinant MVA-PfCSM/MVA-sPfCSM (i.p.); group 3, PfCS14KM (i.d.)/MVA-sPfCSM (i.p.); group 4, parental MVA/MVA (i.p.); and group 5, PBS/PBS (i.p.). (B and C) Comparisons of total CD8+ (B) and CD4+ (C) T cell responses generated by different vaccination schedules during the adaptive and memory phases. Splenocytes from vaccinated mice were obtained at 2 weeks (adaptive) or 10 weeks (memory) postboost. Splenocytes were stimulated in vitro by use of 10 µg/ml CS protein-specific CD8+ T cell peptide. Data are representative of two independent experiments (n = 4 mice/group). (D) Sera from mice (vaccinated as described for panel A) at the memory phase were analyzed by ELISA for the levels of PICs-specific IgG antibodies. (Left) Data are presented as OD450 values versus serum dilutions; the maximum OD is represented by a value of 3.5 (data correspond to the means for 4 animals per group and 3 repeats per animal). (Right) CS protein-specific IgG titers. The titer was defined as the inverse of the highest serum dilution that exhibited at least 3 times the mean OD for the naive control (the presented data correspond to individual mouse titers for 4 animals/group and are means for 3 repetitions per mouse). Statistical analysis was used to compare the PfCS14KM prime/MVA-sPfCSM boost group with all other groups. ***, P < 0.001.
A27 protein in oligomer form and to evaluate its effectiveness in a mouse preclinical setting, alone or combined with an MVA vector expressing PfCS. We generated PfCS immunogens based on a recombinant chimeric protein (PfCS14K) and recombinant MVA (MVA-PfCS). As mice would not produce PfCS-specific T cells in response to this

**FIG 5** PfCS-specific CD8⁺ T cell polyfunctionality in mice. Splenocytes from vaccinated mice were stimulated with 10 μg/ml CS protein-specific peptide. Live lymphocytes were gated on CD3 and then gated on CD8. CD8⁺ T cells were further gated on the memory markers CD127 and CD62L (for samples collected at the memory phase). Gated CD8⁺ T cells were probed for polyfunctionality based on secretion of different combinations of IFN-γ, TNF-α, IL-2, and CD107a. (A) Polyfunctional CS protein-specific CD8⁺ T cells during the adaptive phase. (B) Polyfunctional CS protein-specific CD8⁺ T cells during the memory phase. Data are representative of two independent experiments (n = 4 mice/group). Pie charts compare polyfunctional CD8⁺ T cell populations induced by the distinct immunization schedules during the adaptive and memory phases. Peptide-specific T cells that secreted one, two, three, or all four factors (IFN-γ, TNF-α, IL-2, and CD107a) were classified based on intracellular cytokine staining (ICS). Statistical significance between the PBS prime/PBS boost control group and the PfCS14K⁺ prime/MVA-sPfCSM boost test group is indicated. *, P < 0.05; **, P < 0.005; ***, P < 0.001.
antigen, we generated a mutated PfCS-based recombinant protein (PfCS14KM) and viral immunogen (MVA-sPfCSM) with an H-2K-restricted CD8^+ T cell epitope. For challenge in the mouse model, we used transgenic P. berghei sporozoites expressing full-length PfCS with the CD8^+ T cell epitope. We found that the combined PfCS14KM/MVA-sPfCSM immunization protocol offered protection against malaria that correlated with induction of PfCS-specific CD8^+ T cell and antibody responses.

RTS,S vaccine trials showed that protection against malaria is mediated by high anti-CS protein antibody titers that wane rapidly (9, 25), and current vaccination strategies do not maintain high levels of circulating anti-CS protein antibodies. A recent study showed that the protection offered by RTS,S appears to be strain specific (for strain 3D7) (26). Human studies using irradiated sporozoites or chloroquine prophylaxis showed that maintenance of IFN-γ-secreting T cells can be used as a surrogate protection marker during preerythrocytic stages (22, 27). A cytotoxic T lymphocyte (CTL)-based malaria vaccine expressing the thrombospondin-related adhesive protein (TRAP) antigen in combination with several T cell epitopes from preerythrocytic antigens also provided sterile protection of 21% of individuals in an adenovirus prime/MVA vector boost regimen; although the protection levels were modest, the study highlighted the importance and feasibility of developing a CD8^+ T cell malaria vaccine (28).

The same group nonetheless also found higher levels of vaccine efficacy with an...
adenovirus-MVA combination expressing ME-TRAP (multiepitope string containing malaria antigens fused to thrombospondin-related adhesion protein), with no apparent protective correlation with CD4<sup>+</sup> or CD8<sup>+</sup> T cell responses (29). Other human studies with an irradiated sporozoite vaccine showed a significant, dose-dependent increase in sporozoite-specific T cells in protected individuals (30, 31). The differences in these immunization protocols might account for the distinct induction of activated T cells for vaccine effectiveness. A CD8<sup>+</sup> T cell malaria vaccine would appear to be more efficient for targeting the preerythrocytic parasite stages.

Here we report a prime-boost vaccine protocol based on a chimeric PfCS construct and a recombinant MVA strain that resulted in an 80% reduction in the liver-stage parasite burden in mice and provided 40% sterile protection against infection following parasite challenge with transgenic *P. berghei* expressing the *P. falciparum* CS protein. In a murine malaria model, we previously showed that induction of a large *P. yoelii* CS protein-specific polyfunctional CD8<sup>+</sup> T cell repertoire after priming with multimeric CS14K and boosting with an MVA vector expressing PyCS can induce sterile protection (8). We also found that the CS14K protein triggers a Th1 signaling cascade via IRF-3 and

**FIG 7** PICS14K<sup>+</sup> prime/MVA-sPICS<sup>+</sup> boost immunization protects mice against chimeric *P. berghei* transgenic parasites. (A) At 2 weeks postboost, mice (*n* = 5/group) were challenged intravenously with 2,000 *P. berghei* sporozoites expressing mutated PfCS bearing the CD8<sup>+</sup> T cell epitope DYENDIEKKI (Pb-PfCSM) (left) or unmodified full-length PfCS (Pb-PfCS) (right). After 40 h, the liver parasitemia level was evaluated by RT-qPCR. The percent reduction in liver-stage transgenic parasite development compared to the level for the control groups was determined. (B) Kaplan-Meier survival curves for mice (*n* = 10/group) vaccinated with PICS14K<sup>+</sup>/MVA-sPICS<sup>+</sup> or with PBS/wild-type MVA after challenge with mosquitoes harboring *P. berghei* PICS<sup>+</sup>-transgenic parasites. Statistical significance was determined for differences between the PBS/MVA controls and the protected group. *P* < 0.05.
STAT-1 activation. Here we used a similar strategy to demonstrate that the *P. yoelii* results can be extended to the human malaria antigen PfCS and that high levels of specific CD8\(^+\) T cells and anti-PfCS antibodies can be obtained by this strategy.

To assess the *in vivo* effectiveness of the chimeric immunogen, we generated a new transgenic *P. berghei* strain harboring full-length PfCS with the H-2\(^k\)-restricted cytotoxic epitope DYENDIEKKI. This chimeric line was compared to a transgenic *P. berghei* line expressing unmutated full-length PfCS in which the C-terminal region was not modified but retained the original 3D7 sequence (DYANDIEKKI). The cytotoxic DYENDIEKKI epitope is found naturally in certain *P. falciparum* isolates (such as 7G8 and T4) and is recognized by H-2\(^k\) C3H mice (20). The availability of these two transgenic lines allowed us to assess protection based on PfCS-specific CD8\(^+\) T cells as well as antibodies.

Although the protein/protein- and protein/MVA-immunized mice had similar PfCS-specific antibody levels, liver infection was inhibited only in those that received the mutated chimeric protein and recombinant virus bearing the DYENDIEKKI epitope. The same vaccine regimen with unmutated antigens (PfCS14K/MVA-PfCS) did not protect mice challenged with the *P. berghei* transgenic parasite expressing unmutated PfCS. The protection conferred by the heterologous prime/boost strategy thus suggests an important role for DYENDIEKKI epitope-specific CD8\(^+\) T cells. PfCS14KM/PfCS14KM immunization induced high levels of anti-PfCS antibodies, low levels of CD8\(^+\) T cells, and no parasite protection, whereas the PfCS14KM/MVA-sPfCSM vaccination induced high anti-PfCS titers, high levels of specific CD8\(^+\) T cells, and protection from parasite infection. These findings suggest that parasite inhibition in this system is based at least partly on CD8\(^+\) T cells. We nonetheless cannot rule out that the combined action of PfCS antibodies and specific CD8\(^+\) T cells contributes to parasite inhibition in the protein/MVA-treated group. It would be interesting to compare the biological properties of the PfCS antibodies induced by the PfCS14KM/PfCS14KM and PfCS14KM/MVA-sPfCSM protocols. Parasite protection should be more complete when both PfCS CD8\(^+\) T cells and anti-PfCS antibodies are produced.

Numerous studies have shown that a strong T cell-mediated response correlates with malaria protection (22, 27, 30). The requirement for high CS protein-specific CD8\(^+\) T cell levels for sterile protection is a hurdle that current vaccination strategies must overcome. The high levels of polyfunctional CS protein-specific CD8\(^+\) T cells and of PfCS-specific antibodies generated by our heterologous PfCS14KM/MVA-sPfCSM vaccination regimen suggest its potential as an improved malaria vaccine. Exhaustion of T cell responses, characterized by a loss of polyfunctionality with age, is considered an important factor in *Trypanosoma cruzi* infection in adults compared to that in children (32). The shift in CD8\(^+\) T cell polyfunctionality observed in our experiments during the memory phase compared to the adaptive phase might be beneficial. Analysis of the memory CD8\(^+\) T cell phenotype showed mainly T\(_E\) and T\(_EM\) cells, which coincides with our previous observations and with studies using an irradiated sporozoite vaccine (8, 33). This spectrum of results indicates the complexity of the CS protein-specific CD8\(^+\) T cell functions generated by distinct vaccination protocols.

Considering the evidence that indicates a critical role for PfCS-specific antibodies in protection, our results suggest that vaccine-induced T cell responses can also play a significant role in malaria protection. Other mouse studies using *P. yoelii* showed the importance of CS protein-specific CD8\(^+\) T cells in mediating protection against this parasite, but such a role has not been reported for PfCS in a murine model. Our findings with transgenic *P. berghei* parasites and protein/MVA immunogens suggest a role for PfCS-specific CD8\(^+\) T cells in malaria protection. The combined PfCS14KM/MVA-sPfCSM immunization protocol, which generates strong CD8\(^+\) T cell and antibody responses to PfCS, together with inhibition of *P. berghei* parasites, may have value in an antimalarial vaccine regimen.

**MATERIALS AND METHODS**

**Cells, plasmid, and viruses.** Established chick DF-1 and primary chicken embryo fibroblast (CEF) cells were grown in Dulbecco’s modified Eagle's medium (DMEM) supplemented with 10% heat-
inactivated fetal calf serum (FCS), as described previously (34–36). Cell cultures were maintained at 37°C (CEF) or 39°C (DF-1) in a humidified incubator (85%) with 5% CO₂.

The pCYA-20/sPfCSM plasmid was generated to insert the nearly full-length PfCSM sequence, with the Δ116 → Epsf amino acid substitution, and an additional synthetic secretion signal from the HIV-1 gp120 protein into the thymidine kinase (TK) locus of MVA. The single amino acid substitution was made to incorporate a cytotoxic CD8+ T cell epitope (DYENDIEKKI) not present in the P. falciparum 3D7 strain but found in other P. falciparum isolates, such as 7G8 and T4. Wild-type MVA and the recombinant virus MVA-sPfCSM used for in vivo studies were grown in CEF cells, purified, and titrated as described previously (34).

Construction and characterization of MVA-sPfCSM. To generate the recombinant MVA construct, DF-1 cells (cultured in 6-cm plates to 70% confluence) were infected with wild-type MVA at 0.01 PFU/ml (1 h) and transfected with 8 μg pCYA-20/sPfCSM plasmid by use of Lipofectamine (Invitrogen) to allow insertion of the antigen sequence into the virus TK locus. Cells were harvested at 48 h postinfection, when cytopathic effect was observed. The pCYA-20/sPfCSM plasmid includes the β-galactosidase marker gene between two identical TK locus-flanking regions within the sequence to be inserted into the viral genome. In the first stage, the recombinant virus was isolated by serial plaque passages, using S-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) (1 mg/ml; Sigma-Aldrich) as a substrate for the selection marker. After four passages, plaques negative for β-galactosidase activity were selected and tested for expression of secreted PfCSM in supernatants. After six continuous passages, a recombinant virus free of wild-type contamination was isolated. Virus stocks were analyzed by PCR and Western blotting for the presence and expression of the antigen sequence. For PCR analysis, we used primers targeting the TK locus (Tk FORWARD and Tk REVERSE; Table S3) to confirm the presence of the TK locus.

Protein purification. The PfCS14K and PfCS14KM proteins were purified from Escherichia coli (BL21 transformed with the pGEX-6P-PfCS14K and pGEX-6P-PfCS14KM vectors, respectively. Bacteria were grown at 37°C to an optical density of 0.6 to 0.7. Following induction with 1 mM IPTG (isopropyl-β-D-thiogalactopyranoside), cultures were incubated at 30°C for 5 h before harvesting. Cells were suspended in extraction buffer (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, and protease inhibitor cocktail), lysed using a French press (Thermo Scientific), and centrifuged, and the clarified lysate was incubated with glutathione Sepharose 4B beads (GE Life Sciences) at 4°C overnight. The beads were washed three times with extraction buffer containing 0.5% Triton X-114, followed by three washes with extraction buffer alone. Protein was eluted using 20 mM reduced glutathione in extraction buffer. Purified proteins were dialyzed and dialyzed against 50 mM Tris-HCl, pH 7.5, and 150 mM NaCl. The glutathione S-transferase (GST) tag was cleaved using PreScission protease (GE Life Sciences) according to the manufacturers' instructions. The cleaved protein was further purified to homogeneity by use of HiTrap MonoQ anion columns (GE Life Sciences). The protein was dialyzed against phosphate-buffered saline (PBS) and concentrated using centrifugal concentrators (Millipore). Proteins were tested for endotoxin contamination by use of a Limulus amoebocyte lysate (LAL) kit (Lonza), which indicated the presence of <10 endotoxin units (EU)/μg protein.

SDS-PAGE analysis of protein. Recombinant proteins were analyzed by SDS-PAGE with Coomassie blue staining or by Western blotting using the anti-P. falciparum CSP CS protein MAb 2A10 (8). Briefly, proteins were mixed with 4× Laemmli buffer and separated by 7% SDS-PAGE alone and with β-mercaptoethanol (nonreducing and reducing conditions, respectively). For immunoblots, proteins transferred to nitrocellulose membranes were detected using MAb 2A10 (1:1,000 dilution) followed by goat anti-mouse antibody (1:2,000; Sigma).

Animals and immunizations. The Ethical Committee of Animal Experimentation at the Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB-CSIC) followed by a goat anti-mouse antibody (1:2,000; Sigma). Female C3H/HeNHsd mice (H-2K) aged 5 to 8 weeks were obtained from Harlan Laboratories and used for immunogenicity studies, female C57BL/6 mice aged 5 to 8 weeks were used for parasite characterization, Swiss Webster mice were used for parasite cloning/selection, and female C3H/HeNCr MTV (mammary tumor virus negative; H-2K) mice aged 5 to 8 weeks (Charles River) were used for challenge studies (34). Several homologous or heterologous prime/boost immunization protocols were used to assay fusion protein immunogenicity (see the text and the figure legends). The PFC14K protein was administered intradermally (i.d.), whereas recombinant MVA-sPfCSM was administered by the intraperitoneal (i.p.) route. The amount of protein given to each mouse was 20 μg in PBS for each priming dose, and that of virus was 2 × 10⁷ PFU/mouse for each booster dose. Mice were sacrificed at 2 weeks (adaptive response) or 2 months (memory response) postboost for studies of immune responses. Two independent experiments were performed.

Transgenic sporozoite generation and challenge. To develop the chimeric line P. berghei-P. falciparum CSP-FL CD8CT, a 784-bp restriction fragment encompassing bp 246 to 1029 of the P. berghei-P. falciparum CSP NT csp csp gene was excised from the plasmid pIC-CSPINT (37) by use of the restriction enzymes BbsI and PacI (New England Biolabs). This portion was replaced with a 943-bp fragment which was released by using the same restriction enzymes and the pHZ-PfCSP plasmid. The csp gene (1,188 bp) in the resulting plasmid, pIC-CSPFL-CD8CT, consisted of a full-length P. falciparum 3D7 CS protein in which the signal sequence was replaced with that from the P. berghei CS protein (bp 1 to 69). In addition, a single base pair in the plasmid pIC-CSPFL-CD8CT CS gene was replaced to incorporate a cytotoxic epitope not present in the P. falciparum 3D7 strain. This change was introduced at bp 1079 by site-directed mutagenesis using a QuikChange II XL site-directed mutagenesis kit (Agilent Technol-
TTATGTGCATTGCT). DNA isolated from chimeric parasites was sequenced to verify the replaced gene.

The primers used to verify integration at the 3' end were PbCSS-F (TGCCC TATTCCTATATTACAC) and hDHRF5-UTR-R (CACCATTTTTGAAAAGATTAATTTGA), and the primers used to confirm 5' integration were PbCS3-UTR-R (CGCC TTAATGCGATTGCT). DNA isolated from chimeric parasites was sequenced to verify the replaced gene.

Challenge studies to determine liver-stage parasitemia were performed as described previously (8, 40). Briefly, 2,000 sporozoites isolated from salivary glands of Anopheles stephensi mosquitoes were injected into the tail veins of mice. After 42 h, mice were euthanized, and their liver parasitemia levels were assessed by quantitative reverse transcription-PCR (RT-qPCR) as described previously (40). To evaluate blood-stage parasitemia after vaccination, 5 P. berghei-P. falciparum CSP-FL CD8CT-infected mosquitoes were allowed to feed on immunized mice for ~10 min, and the presence of parasites in blood was determined by examination of Giemsa-stained blood smears on days 4 to 14 after infection; the survival probability for challenged mice in this experiment was calculated relative to the time to patentcy, measured in days.

**Multivariate flow cytometry.** The levels, polyfunctionality, and phenotypes of PCS-specific T cell responses in the adaptive and memory phases were analyzed by flow cytometry and intracellular cytokine staining (ICS) as described previously (41). Briefly, 4 × 10^6 splenocytes were stimulated with 10 μg/ml CD8+ T cell-specific epitope DYENDIEKKI (based on the sequences of P. falciparum 7G8 and T4 isolates [20]; obtained from Peptide 2.0 Inc.), 1 μg/ml GolgiPlug (BD Biosciences), anti-CD107a–Alexa 488 (BD Biosciences), and monensin (1 μM; eBioscience) in RPMI 1640 medium supplemented with 10% fetal calf serum (6 h) in a 96-well plate. In the case of samples stimulated with PICS (Pfenex; produced in Pseudomonas fluorescens), splenocytes were incubated with 10 μg/ml protein and anti-CD107a–Alexa 488 (2 h) followed by GolgiPlug and monensin as described above (4 h). Following stimulation, cells were washed and their FC receptors blocked by use of anti-CD16/CD32 (BD Biosciences), and the cells were then stained for surface markers, fixed, permeabilized (Cytofix/Cytoperm kit; BD Biosciences), and stained intracellularly for cytokines with appropriate fluorochromes. Dead cells were excluded by use of a violet LIVE/DEAD staining kit (Invitrogen). Cells were stained with mouse antibodies, including CD3-phycoerythrin (PE)-CF594, CD4-allophycocyanin (APC)-Cy7, CD8-V500, IFN-γ–PE–Cy7, IL-2–APC, and TNF-α–PE (all from BD Biosciences). For differentiation of memory T cells, we used CD62L-Alexa 700 (BD Biosciences) and CD127-peridinin chlorophyll protein (PerCP)-Cy5.5 (eBioscience) antibodies (only the memory PCS-specific CD8+ T cells that expressed any of the analyzed cytokines were selected and represented). Cells (10^6) were passed through a Gallios flow cytometer (Beckton Coulter), and data were analyzed with FlowJo (Tree Star Inc.). Appropriate controls were used, and values for unstimulated samples were subtracted.

**Antibody measurement by ELISA.** Antibodies against the CS protein were determined by enzyme-linked immunosorbent assay (ELISA) performed on sera from immunized mice in the memory phase, as previously described (8). Serum samples from individual mice of each naive and immunized group were serially diluted 2-fold in triplicate and incubated with purified recombinant CS protein (2 μg/ml; Pfenex)-coated plates. The CS protein-specific IgG data are depicted as the mean OD450 for each dilution obtained for each group (OD graph).

**Data analysis.** Statistical analysis was performed using Minitab for Windows. One-way analysis of variance (ANOVA) was used to determine the statistical significance of differences between groups. For ICS, statistical analysis was based on previously described methods (8, 36, 41).

**ACKNOWLEDGMENTS**

We thank Victoria Jiménez for expert technical assistance with cell culture, virus growth, and purification and Catherine Mark for editorial assistance.

D.A.E. and F.Z. thank the Bloomberg family foundation for continued support. This work was supported in part by Spanish grant SAF2013-45232R. E.M.-P. was supported by a Formación del Profesorado Universitario fellowship from the Spanish Ministry of Health and Education, and A.V. and S.C.R. were recipients of La Caixa Ph.D. fellowships.

**REFERENCES**

1. Singh AP, Buscaglia CA, Wang Q, Levy A, Nussenzweig DR, Walker JR, Winzeler EA, Fuji H, Fontoura BMA, Nussenzweig V. 2007. Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 131:492–504. https://doi.org/10.1016/j.cell.2007.09.013.

2. Pinzon-Ortiz C, Friedman J, Esko J, Sinnis P. 2001. The binding of the circumsporozoite protein to cell surface heparan sulfate proteoglycans is required for plasmodium sporozoite attachment to target cells. J Biol Chem 276:26784–26791. https://doi.org/10.1074/jbc.M104038200.

3. Coppi A, Natarajan R, Pradel G, Bennett BL, James ER, Roggero MA,
Corradin G, Peterson C, Tewari R, Sinha P. 2011. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J Exp Med 208:341–356. https://doi.org/10.1084/jem.20101488.

4. Mishra S, Nussenzenwag RS, Nussenzenwag V. 2012. Antibodies to Plasmodium circumsporozoite protein (CSP) inhibit sporozoite’s cellular traversal activity. J Immunol Methods 377:47–52. https://doi.org/10.1016/j.jim.2012.01.009.

5. Foquet L, Hermsen CC, van Gemert GJ, Van Braeckel E, Weening KE, Sauerwein R, Meuleman P, Leroux-Roels G. 2014. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J Clin Invest 124:140–144. https://doi.org/10.1172/JCI70349.

6. Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, Voss G, Kester KE, Heppner DG, Krzych U. 2003. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol 171:6961–6967. https://doi.org/10.4049/jimmunol.171.12.6961.

7. Huang J, Tsoa T, Zhang M, Tsuji M. 2014. Circumsporozoite protein-specific K(d)-restricted CD8+ T cells mediate protective antimalarial immunity in sporozoite-immunized MHC-I-K(d) transgenic mice. Media tors Inflamm 2014:728939. https://doi.org/10.1155/2014/728939.

8. Vijayan A, Gómez CE, Espinosa Da, Do Carmo SA, Sorzano COS, Zavala F, Esteban M. 2012. Adjuvant-like effect of vaccinia.4049/jimmunol.1102492.

9. Kester KE, Cummings JF, Ofiri-Anyiam O, Ockenhouse CF, Krzych U, Morris P, Schwenk R, Nielsen RA, Edebe Z, Pinelis E, Juompan L, Williams J, Dower M, Stewart VA, Wirtz RA, Dubois MC, Lifven M, Cohen J, Ballou WR, Heppner DG, Jr, RTS, S Vaccine Evaluation Group. 2009. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naïve adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 203:337–346. https://doi.org/10.1086/600120.

10. Schmidt NW, Podomyrin RL, Butler NS, Badovirac VP, Tucker BJ, Bahjat KS, Lauer P, Reyes-Sandoval A, Hutchings CL, Moore AC, Gilbert SC, Hill AV, Marsh KS, Yewdell JW, Trager LR, Darrah PA, Flynn BJ, Becker MR, Udrey MC, Clausen BE, Igayto BA, Kapan DH, Kastenmüller W, Germann RN, Seder RA. 2011. Protective CD8 T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires CD4 T cell co-stimulation and T cellergic, type I IFN, and multiple DC subsets. J Immunol 178:1782–1796. https://doi.org/10.4049/jimmunol.1002416.

11. Qian F, Reiter K, Zhang Y, Shimp RL, Nguyen V, Aebig J, Rausch KM, Zhu D, Lambert L, Mullen GED, Martin LB, Long CA, Miller LH, Narum DL. 2012. Immunogenicity of self-associated aggregates and cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein 1. PLoS One 7:e36996. https://doi.org/10.1371/journal.pone.0036996.

12. Liehl P, Zuzarte-Luis V, Chan J, Zilling T, Baptista F, Carapau D, Konert M, Hanson KK, Carret C, Lassig N, Müller K, Karlke U, Saeed M, Choa AF, Golenbock DT, Preflow WJ, Prudêncio M, Coelho LP, Kappe SH, Superti-Furga G, Pichlmair A, Vigário AM, Fitzgerald KA, Barchet W, Mota MM. 2014. Host-cell sensors for Plasmodium activate innate immunity in primates through mechanisms that involve ferroptosis. Nat Med 20:47–53. https://doi.org/10.1038/nm.3514.

13. Udhayakumar V, Ongecha JM, Shi YP, Aidoo M, Orago AS, Olowo AO, Haywle WA, Nahien BL, Hoffman SL, Weiss WR, Lal AA. 1997. Cytotoxic T cell reactivity and HLA-B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ T cell epitope in naturally exposed Kenyan adults. Eur J Immunol 27:1952–1957. https://doi.org/10.1002/eji.180270819.

14. Vazquez MI, Rivas G, Cregut D, Serrano L, Esteban M. 1998. The vaccinia virus 14-kilodalton (A27L) fusion protein forms a triple-coiled-coil structure and interacts with the 21-kilodalton (A17L) virus membrane protein through a C-terminal alpha-helix. J Virol 72:10126–10137.

15. Chang TH, Chang SJ, Hsieh FL, Ko TP, Lin CT, Ho MR, Wang L, Hsu ST, Guo RT, Chang W, Wang AH. 2013. Crystal structure of vaccinia virus A27 protein reveals a novel structure critical for its function and complex formation with A26 protein. PLoS Pathog 9:e1003563. https://doi.org/10.1371/journal.ppat.1003563.

16. Miyahara Y, Garcia-Sastre A, Rodriguez D, Rodriguez JR, Murata K, Tsuji M, Palese P, Esteban M, Zavala F, Nussenzenwag RS. 1998. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc Natl Acad Sci USA A 95:3954–3959. https://doi.org/10.1073/pnas.95.6.3954.

17. Calvo-Calle JM, Hammer J, Sinaigalla F, Clavijo P, Moya-Castro ZR, Nardin EH. 1997. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J Immunol 159:1362–1373.

18. Epstein JE, Tewari K, Lyke KE, Sim BKL, Billingsley PF, Laurens MB, Chakravarty O, Dwivedi S, Jackson ER, Segapede M, Richman A, Velmurugan S, Rees SL, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR.
Clinical and Vaccine Immunology

Kornisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Ritchie TL, Seder RA. 2011. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334:475–480. https://doi.org/10.1126/science.1211548.

23. Huster KM, Busch V, Schiennmann M, Linkemann K, Kerkisz KM, Wagner H, Busch DH. 2004. Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc Natl Acad Sci U S A 101:5610–5615. https://doi.org/10.1073/pnas.0308054101.

24. Salleras L, Gevaert J, Lanuzucovich A. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22:745–763. https://doi.org/10.1146/annurev.immunol.22.012703.104702.

25. White NJ. 2011. A vaccine for malaria. N Engl J Med 365:1926–1927. https://doi.org/10.1056/NEJM1111777.

26. Neafsey DE, Juraska M, Bedford T, Benkeiser D, Valim C, Griggs A, Lievens M, Abdulla S, Adjei S, Agbenyega T, Agnandji ST, Aide P, Anderson S, Andi F, Apostol M, Artenius M, Asong D, Aponte JJ, Asante KP, Bejon P, Birkett AJ, Bruls M, Connolly KM, D’Alessandro U, Doboń C, Gesase S, Greenland B, Grimsby J, Tinto H, Hamel MJ, Hoffman I, Kamathunzi P, Kariuki S, Kiiuru PG, Leach A, Lell B, Lennon NJ, Lusingu J, Marsh K, Martinson F, Molel JT, Moss EL, Mz系M, Njuguna P, Ockenhouse CF, Ogutu B, Olowo D, Otieno K, Owusu-Agyei S, Park DJ, Pellé K, Robbins D, Russ C, Ryan EM, Sack BK, Salleras L, Sanchis-Gomar F, Schofield CJ, Tapper M, Tabet L, Valea I, Volman SK, Yu Q, Lapierre D, Birren BW, Gilbert PB, Wirth DF. 2015. Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. N Eng J Med 373:2025–2037. https://doi.org/10.1056/NEJMoa1505819.

27. Sacarlal J, Sogoloff B, Sorgho H, Tanner M, Theander T, Valea I, Volkman H, Hamel MJ, Hoffman I, Kamthunzi P, Kariuki S, Kremsner PG, Leach A, Lell B, Lennon NJ, Lusingu J, Marsh K, Martinson F, Molel JT, Moss EL, Mz系M, Njuguna P, Ockenhouse CF, Ogutu B, Olowo D, Otieno K, Owusu-Agyei S, Park DJ, Pellé K, Robbins D, Russ C, Ryan EM, Sack BK, Salleras L, Sanchis-Gomar F, Schofield CJ, Tapper M, Tabet L, Valea I, Volman SK, Yu Q, Lapierre D, Birren BW, Gilbert PB, Wirth DF. 2015. Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. N Eng J Med 373:2025–2037. https://doi.org/10.1056/NEJMoa1505819.

28. Englund J, Sorensen L, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Charlton M, Wilesmith J, Billingsley PF, Gunasekera A, Kappe SH, Davidson SA, Garver LS, Bjorkstrom NK, Nason MC, Plowe CV, Fishbeugher M, Rack B, Kappe SH, Davidson SA, Garver LS, Bjorkstrom NK, Nason MC, Graham BS, Rutledge ME, Simon BK, Hoffman SL, Livermore ME, Gordon IJ, Chang LJ, Ebenzer H, James ER, Ledderow J, Houghton C, Armstrong D, Artenius M, Sjödén C, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Rutledge ME, Simon BK, Hoffman SL, Livermore ME, Gordon IJ, Chang LJ, Ebenzer H, James ER, Ledderow J, Houghton C, Armstrong D, Artenius M, Sjödén C, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL. 2013. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22:614–623. https://doi.org/10.1038/nm.3410.

29. Albareda MC, De Rissio AM, Tomas G, Serjan A, Alvarez MG, Viotti R, Fichera LE, Esteva MI, Potente D, Armenti T, Arletton RL, Laucella SA. 2013. Polyfunctional T cell responses in children in early stages of chronic Trypanosomiasis cruzi infection contrast with monofunctional responses of long-term infected adults. PLoS Negl Trop Dis 7:e2575. https://doi.org/10.1371/journal.pntd.0002575.

30. Morelle D, Lievens M, Ballou RW, Cooke GS, Faust SN, Gilbert S, Hill AV. 2004. Selective expression of IL-7 receptor on memory T cells induced by malaria sporozoites. J Immunol 220:256–262. https://doi.org/10.1186/1475-2875-3-9.

31. Cavalcanti OA, Ochman J, Van Vliet MA, Herbst PE, Lauritzen A, Gibbs RA, LeGendre J, Almeida AL, Mitchell J, Moore J, Villeval VE, Dessein F, D’arrigo C, Gottlieb E, Guimarães RF, Shaw P, Smith G, Stiles P, Turell J, Upcroft P, Verheyen T, Walter J, Walls J, Yount D, Zayas J, Zola H, Zuckerman J, Zúñiga LM, Zúñiga G, Zúñiga A. 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341:1359–1365. https://doi.org/10.1126/science.1241800.

32. Iizuka SA, Lynne KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME, Gordon JJ, Chang LJ, Sarwar UN, Zehir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Chakravarty S, Manojo A, Li M, Ruben AJ, Li T, Eappen AG, Hoffman SL, Rutledge ME, Simon BK, Hoffman SL, Livermore ME, Gordon IJ, Chang LJ, Ebenzer H, James ER, Ledderow J, Houghton C, Armstrong D, Artenius M, Sjödén C, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Rutledge ME, Simon BK, Hoffman SL, Livermore ME, Gordon IJ, Chang LJ, Ebenzer H, James ER, Ledderow J, Houghton C, Armstrong D, Artenius M, Sjödén C, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Rutledge ME, Simon BK, Hoffman SL, Livermore ME, Gordon IJ, Chang LJ, Ebenzer H, James ER, Ledderow J, Houghton C, Armstrong D, Artenius M, Sjödén C, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Rutledge ME, Simon BK, Hoffman SL, Livermore ME, Gordon IJ, Chang LJ, Ebenzer H, James ER, Ledderow J, Houghton C, Armstrong D, Artenius M, Sjödén C, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Rutledge ME, Simon BK, Hoffman SL, Livermore ME, Gordon IJ, Chang LJ, Ebenzer H, James ER, Ledderow J, Houghton C, Armstrong D, Artenius M, Sjödén C, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL.

33. Vijayan A, García-Arriaza J, Raman SC, Conesa JJ, Chichón FJ, Santiago C, Martínez M, Sainz J, Fichera DH. 2004. Selective expression of IL-7 receptor on memory T cells induced by malaria sporozoites. J Immunol 220:256–262. https://doi.org/10.1038/ncomms3836.

34. Cerezo A, Marín P, Peris F, Rodríguez F, Sánchez M, Sánchez M, García-Arriaza J, Van Vliet MA, Torres A, Sainz J, Fichera DH. 2005. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341:1359–1365. https://doi.org/10.1126/science.1241800.

35. Iizuka SA, Lynne KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME, Gordon JJ, Chang LJ, Sarwar UN, Zehir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Chakravarty S, Manojo A, Li M, Ruben AJ, Li T, Eappen AG, Hoffman SL, Rutledge ME, Simon BK, Hoffman SL, Livermore ME, Gordon IJ, Chang LJ, Ebenzer H, James ER, Ledderow J, Houghton C, Armstrong D, Artenius M, Sjödén C, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL. 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341:1359–1365. https://doi.org/10.1126/science.1241800.